

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

TRADING HALT

At the request of Shanghai Haohai Biological Technology Co., Ltd. (the “**Company**”), trading in the H shares of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 1:00 p.m. on Tuesday, 15 November 2016 pending the release of an announcement by the Company in relation to a discloseable transaction of the Company involving the acquisition of an ophthalmology products trading company in Shenzhen. The signing of the relevant equity transfer agreement constitutes inside information of the Company due to its strategic importance in the ophthalmology industry sector.

By Order of the Board

Shanghai Haohai Biological Technology Co., Ltd.

Chairman

Hou Yongtai

Shanghai, 15 November 2016

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ming and Ms. Chen Yiyi; the non-executive directors of the Company are Ms. You Jie and Mr. Gan Renbao; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Li Yuanxu, Mr. Zhu Qin and Mr. Wong Kwan Kit.

** For identification purpose only*